The medical product Zonisamid EQL Pharma has now been approved for sale by the Danish Medicines Agency.

Zonisamid EQL Pharma is an anticonvulsant being used in the treatment of epilepsy. The name of the original product is Zonegran (Eisai Limited).

The total turnover of the original product in Denmark is approximately SEK 12 million annually. Currently there are two generic competitors on the market in addition to the original. EQL Pharma aims to start selling Zonisamid EQL Pharma in Q1 2017 at the latest.

"We are pleased that Zonisamid EQL Pharma has now been approved in Denmark and is approaching launch" says Christer Fåhraeus, CEO of EQL Pharma.

For further information, please contact:
Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
Email: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma is specialized in developing and selling generic medicines, i.e. medines that are medically equivalent to the originals. The company currently markets five niche generics in the Swedish and Danish markets, in addition to these, there are a significant pipeline of additional niche generics for launch in 2017 and onwards. The business is currently entirely focused on prescription drugs in the Nordic region. EQL Pharma is based in Lund, employs 6 (7) people and is listed on AktieTorget. The company conducts extensive development of generics in cooperation with leading contract manufacturers and major pharmaceutical companies in countries including India and China.